Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | BCL2L1 | Q07817 | 16/20 | 0.79 |
| ▸ | BCL2 | P10415 | 8/20 | 0.79 |
| ▸ | MCL1 | Q07820 | 8/20 | 0.79 |
| ▸ | BCL2A1 | Q16548 | 4/20 | 0.79 |
| ▸ | BCL2L2 | Q92843 | 1/20 | 0.45 |
| ▸ | IGF1R | P08069 | 1/20 | 0.41 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.41 |
| ▸ | DAO | P14920 | 1/20 | 0.39 |
| ▸ | PTGS1 | P23219 | 1/20 | 0.37 |
| ▸ | PTGS2 | P35354 | 1/20 | 0.37 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.37 |
| ▸ | CYP2A6 | P11509 | 1/20 | 0.37 |
| ▸ | TAAR1 | Q96RJ0 | 1/20 | 0.37 |
| ▸ | BAK1 | Q16611 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2532052 | 0.88 | BCL2L1 (1.00) | BCL2L1BCL2MCL1BCL2A1BCL2L2 | |
| SCHEMBL14995965 | 0.80 | BCL2L1 (0.66) | BCL2L1BCL2MCL1BCL2A1BCL2L2 | |
| SCHEMBL14995970 | 0.78 | BCL2L1 (0.64) | BCL2L1BCL2MCL1BCL2A1BCL2L2 | |
| SCHEMBL2622283 | 0.76 | BCL2L1 (0.60) | BCL2L1BCL2MCL1BCL2A1BCL2L2 | |
| SCHEMBL2528280 | 0.76 | BCL2L1 (0.61) | BCL2L1BCL2MCL1BCL2A1BCL2L2 | |
| SCHEMBL2532050 | 0.75 | BCL2L1 (0.76) | BCL2L1BCL2MCL1BCL2A1BCL2L2 | |
| SCHEMBL353018 | 0.73 | BCL2L1 (1.00) | BCL2L1BCL2MCL1BCL2A1BAK1 | |
| SCHEMBL2529200 | 0.72 | BCL2L1 (0.58) | BCL2L1BCL2MCL1BCL2A1BCL2L2 | |
| SCHEMBL19420195 | 0.71 | BCL2L1 (0.95) | BCL2L1BCL2MCL1BCL2A1BAK1 | |
| SCHEMBL10112851 | 0.69 | BCL2L1 (0.78) | BCL2L1BCL2MCL1BCL2A1BAK1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8937193-B2 | Apogossypolone derivatives as anticancer agents | SANFORD-BURNHAM MEDICAL RESEARCH INSTITUTE (US) | 2015-01-20 | — | — | US | disclosed |
| US-20110112112-A1 | APOGOSSYPOLONE DERIVATIVES AS ANTICANCER AGENTS | SANFORD-BURNHAM MEDICAL RESEARCH INSTITUTE (US) | 2011-05-12 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110112112-A1 | APOGOSSYPOLONE DERIVATIVES AS ANTICANCER AGENTS | CYP17A1, HSD17B7, CYP27A1 | BCL2L1 195/4885BCL2 142/4885MCL1 34/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.